NEW YORK – BioSkryb Genomics and 1Cell.Ai said Thursday that they have signed a strategic partnership to create a platform for analyzing rare cell populations such as circulating tumor cells (CTCs).
Under the terms of the deal, the firms will codevelop a product for analyzing rare cell populations by merging BioSkryb's single-cell amplification and multiomics chemistry with 1Cell.Ai's OncoIncytes cell isolation platform.
In addition, 1Cell.Ai's CLIA laboratory in Foster City, California, and BioSkryb's services laboratory in Durham, North Carolina, will both analyze customer samples.
The partnership will initially last three years and use a revenue-sharing model. Other financial terms were not disclosed.
"With this integrated platform, researchers can now isolate CTCs at one in a billion and characterize DNA, RNA, and protein targets from these individual single cells with unprecedented precision," the firms said in a statement.
BioSkryb, a spinout from St. Jude Children's Research Hospital, offers the ResolveOme assay, based on patented DNA amplification technology, for combined whole-genome and full-length transcriptome sequencing in single cells. It also offers cell surface protein analysis as a service, among others.
1Cell.Ai, formerly OneCell Diagnostics, offers the OncoIncytes platform, which captures and isolates live single cells from blood, facilitating the detection of protein targets for the development of drugs, including antibody-drug conjugates. The firm raised a $16 million Series A financing round in November.